CytomX Therapeutics (CTMX) Enterprise Value: 2014-2025
Historic Enterprise Value for CytomX Therapeutics (CTMX) over the last 11 years, with Sep 2025 value amounting to $382.4 million.
- CytomX Therapeutics' Enterprise Value rose 1605.15% to $382.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $43.9 million, marking a year-over-year increase of 109.00%. This contributed to the annual value of -$20.0 million for FY2024, which is 71.68% up from last year.
- Per CytomX Therapeutics' latest filing, its Enterprise Value stood at $382.4 million for Q3 2025, which was up 1,434.49% from $24.9 million recorded in Q2 2025.
- Over the past 5 years, CytomX Therapeutics' Enterprise Value peaked at $382.4 million during Q3 2025, and registered a low of -$108.5 million during Q2 2022.
- Moreover, its 3-year median value for Enterprise Value was -$29.0 million (2025), whereas its average is -$5.6 million.
- Over the last 5 years, CytomX Therapeutics' Enterprise Value had its largest YoY gain of 1,605.15% in 2025, and its largest YoY loss of 992.45% in 2025.
- Over the past 5 years, CytomX Therapeutics' Enterprise Value (Quarterly) stood at -$22.7 million in 2021, then plummeted by 287.34% to -$87.9 million in 2022, then climbed by 19.61% to -$70.7 million in 2023, then skyrocketed by 71.68% to -$20.0 million in 2024, then spiked by 1,605.15% to $382.4 million in 2025.
- Its Enterprise Value was $382.4 million in Q3 2025, compared to $24.9 million in Q2 2025 and -$29.0 million in Q1 2025.